Platelet-activating factor receptor (PAF-R)-dependent pathways control tumour growth and tumour response to chemotherapy

BMC Cancer

Volumn 10, Issue , 2010, Pages

  de Oliveira, Soraya I ^a   Andrade, Luciana N S ^a   Onuchic, Ana C ^a   Nonogaki, Sueli ^c   Fernandes, Patrícia D ^b   Pinheiro, Mônica C ^a   Rohde, Ciro B S ^a   Chammas, Roger ^a   Jancar, Sonia ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c INSTITUTO ADOLFO LUTZ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BEPAFANT; CASPASE 3; CYCLOOXYGENASE 2; DACARBAZINE; GALECTIN 3; NITRIC OXIDE; PROSTAGLANDIN E2; PROTEIN ANTIBODY; THROMBOCYTE ACTIVATING FACTOR RECEPTOR; THROMBOCYTE ACTIVATING FACTOR RECEPTOR ANTIBODY; UNCLASSIFIED DRUG; VASCULOTROPIN; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; AZEPINE DERIVATIVE; CASP3 PROTEIN, MOUSE; FIBRINOGEN RECEPTOR; G PROTEIN COUPLED RECEPTOR; PTGS2 PROTEIN, MOUSE; TRIAZOLE DERIVATIVE; VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE; VASCULOTROPIN A;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; ASCITES; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER INHIBITION; CANCER SIZE; CANCER SURVIVAL; CAPILLARY DENSITY; CONTROLLED STUDY; DRUG TARGETING; EHRLICH ASCITES TUMOR; EHRLICH ASCITES TUMOR CELL; FEMALE; MACROPHAGE; MALE; MELANOMA; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; TREATMENT RESPONSE; ANIMAL; BAGG ALBINO MOUSE; C57BL MOUSE; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPERIMENTAL MELANOMA; FLOW CYTOMETRY; IMMUNOHISTOCHEMISTRY; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SIGNAL TRANSDUCTION; TIME; TUMOR VOLUME; VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; AZEPINES; CARCINOMA, EHRLICH TUMOR; CASPASE 3; CELL PROLIFERATION; CYCLOOXYGENASE 2; DACARBAZINE; DINOPROSTONE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; GALECTIN 3; IMMUNOHISTOCHEMISTRY; MACROPHAGES; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; NITRIC OXIDE; PHENOTYPE; PLATELET MEMBRANE GLYCOPROTEINS; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; TIME FACTORS; TRIAZOLES; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77952038260     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-200     Document Type: Article

References (31)

1. Mantovani A, Sica A, Locati M. Macrophage polarization comes of age. Immunity 2005, 23:344-6. 10.1016/j.immuni.2005.10.001, 16226499.
2. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nature Reviews 2005, 5:953-64.
3. Fadok VA, Bratton DL, Konowal A, et al. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2 and PAF. J Clin Invest 1998, 101:890-8. 10.1172/JCI1112, 508637, 9466984.
4. Fadok VA, Bratton DL, Henson PM. Phagocyte receptors for apoptotic cells: recognition, uptake, and consequences. J Clin Invest 2001, 108:957-62. 200959, 11581295.
5. Oliveira SI, Fernandes PD, Mendes Amarante JG, et al. Phagocytosis of apoptotic and necrotic thymocytes is inhibited by PAF-receptor antagonists and affects LPS-induced COX-2 expression in murine macrophages. Prostaglandins Other Lipid Mediat 2006, 80:62-73. 10.1016/j.prostaglandins.2006.04.002, 16846787.
6. Griffiths RJ. Prostaglandins and inflammation. Inflammation: Basic Principles and Clinical Correlates 1999, 249-65. Lippincott & Wilkins, Philadelphia, Gallin JI, Snyderman R.
7. Honda Z, Ishii S, Shimizu T. Platelet-activating factor receptor. J Biochem 2002, 131:773-9.
8. Correa M, Machado J, Carneiro CR, et al. Transient inflammatory response induced by apoptotic cells is an important mediator of melanoma cell engraftment and growth. Int J Cancer 2005, 114:356-63. 10.1002/ijc.20673, 15573371.
9. Bussolati B, Biancone LM, Cassoni P, et al. PAF produced by human breast cancer cells promotes migration and proliferation of tumor cells and neo-angiogenesis. Am J Pathol 2000, 157:1713-25. 1885724, 11073830.
10. Im SY, Ko HM, Kim JW, et al. Augmentation of tumor metastasis by platelet-activating factor. Cancer Res 1996, 56:2662-5.
11. Fecchio D, Russo M, Sirois P, et al. Inhibition of Ehrlich ascitis tumor in vivo by PAF-antagonists. Int J Immunopharmacol 1990, 12:57-65. 10.1016/0192-0561(90)90068-X, 2303318.
12. Fecchio D, Sirois P, Russo M, Jancar S. Studies on the inflammatory response induced by Ehrlich ascitis tumor in mice. Inflammation 1990, 14:125-32. 10.1007/BF00914035, 2323805.
13. Wack C, Becker JC, Brocker EB, et al. Chemoimmunotherapy for melanoma with dacarbazine and 2,4-dinitrochlorobenzene: results from a murine tumor model. Melanoma Res 2001, 11:247-53. 10.1097/00008390-200106000-00006, 11468513.
14. Cruz-Munoz W, Man S, Kerbel RS. Effective treatment of advanced human melanoma metastasis in immunodeficient mice using combination metronomic chemotherapy regimens. Clin Cancer Res 2009, 15:4867-74. 10.1158/1078-0432.CCR-08-3275, 19622578.
15. Bartholomew B. A rapid method for the assay of nitrate in urine using the nitrate reductase enzyme of Escherichia coli. Food Chem Toxicol 1984, 22:541-3. 10.1016/0278-6915(84)90224-2, 6378739.
16. Coutinho EL, Andrade LN, Chammas R, et al. Anti-tumor effect of endostatin mediated by retroviral gene transfer in mice bearing renal cell carcinoma. FASEB J 2007, 21:3153-61. 10.1096/fj.07-8412com, 17513560.
17. Novak EM, Metzger M, Chammas R, et al. Downregulation of TNF-alpha and VEGF expression by Sp1 decoy oligodeoxynucleotides in mouse melanoma tumor. Gene Ther 2003, 10:1992-7. 10.1038/sj.gt.3302111, 14528323.
18. Ghosh S, Roy Banerjee SM, et al. Moulation of tumor induced angiogenesis in Ehrlich ascitis tumor. J Exp Clin Cancer Res 2004, 23:681-90.
19. Zimmerman GA, McIntyre TM, Prescott SM, et al. The Platelet-activating factor signaling system and its regulators in syndromes of inflammation and thrombosis. Crit Care Med 2002, 30:S294-S301. 10.1097/00003246-200205001-00020, 12004251.
20. Prescott SM, Zimmerman GA, Stafforini DM, et al. Platelet-activating factor and related lipid mediators. Annu Rev Biochem 2000, 69:419-45. 10.1146/annurev.biochem.69.1.419, 10966465.
21. Ko HM, Jung HH, Seo KH, et al. Platelet-activating factor-induced NF-kappaB activation enhances VEGF expression through a decrease in p53 activity. FEBS Lett 2006, 580:3006-12. 10.1016/j.febslet.2006.04.042, 16684540.
22. Biancone L, Cantaluppi V, Sorbo Del L, et al. Platelet-activating factor inactivation by local expression of platelet-activating factor acetyl-hydrolase modifies tumor vascularization and growth. Clin Cancer Res 2003, 9:4214-20.
23. Casals-Stenzel J. Triazolodiazepines are potent antagonists of PAF in vitro and in vivo. Naunyn Schiedeberg's Arch Pharmacol 1987, 335:351-5.
24. Kim JJ, Tannock IF. Repopulation of cancer cells during therapy: an important cause of treatment failure. Nat Rev Cancer 2005, 5:516-25. 10.1038/nrc1650, 15965493.
25. Tredan O, Galmarini CM, Patel K, et al. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007, 99:1441-54. 10.1093/jnci/djm135, 17895480.
26. Seo KH, Ko HM, Kim HA, et al. Platelet-activating factor induces up-regulation of antiapoptotic factors in a melanoma cell line through nuclear factor-kappaB activation. Cancer Res 2006, 66:4681-6. 10.1158/0008-5472.CAN-05-2766, 16651419.
27. Pollard JW. Tumor-educated macrophages promote tumor progression and metastasis. Nat Rev Cancer 2004, 4:71-8. 10.1038/nrc1256, 14708027.
28. Karlsson A, Christenson K, Matlak M, et al. Galectin-3 functions as an opsonin and enhances the macrophage clearance of apoptotic neutrophils. Glycobiology 2009, 19:16-20. 10.1093/glycob/cwn104, 18849325.
29. Hsu DK, Chernyavsky AI, Chen HY, et al. Endogenous galectin-3 is localized in membrane lipid rafts and regulates migration of dendritic cells. J Invest Dermatol 2009, 129:573-83. 10.1038/jid.2008.276, 2645233, 18843294.
30. MacKinnon AC, Farnworth SL, Hodkinson PS, et al. Regulation of alternative macrophage activation by galectin-3. J Immunol 2008, 180:2650-8.
31. Dumont P, Berton A, Nagy N, et al. Expression of galectin-3 in the tumor immune response in colon cancer. Lab Invest 2008, 88:896-906. 10.1038/labinvest.2008.54, 18542048.